Clinical Trial: A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

U.S., July 12 -- ClinicalTrials.gov registry received information related to the study (NCT07060989) titled 'A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation' on July 02.

Brief Summary: This study is to evaluate the safety, tolerability, PK, and preliminary efficacy of NTS071 in adults with TP53 Y220C-mutated solid tumors.

Study Start Date: Aug., 2025

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumors

Intervention: DRUG: NTS071

Oral administration

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Nutshell Therapeutics (Shanghai) Co., LTD.

Disclaimer: Curated by HT Syndication....